Free Trial
NASDAQ:ELUT

Elutia (ELUT) Stock Price, News & Analysis

Elutia logo
$0.82 -0.06 (-6.69%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$0.82 +0.00 (+0.49%)
As of 11/13/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Elutia Stock (NASDAQ:ELUT)

Advanced

Key Stats

Today's Range
$0.79
▼
$0.88
50-Day Range
$0.74
▼
$0.93
52-Week Range
$0.50
▼
$1.39
Volume
50,440 shs
Average Volume
77,118 shs
Market Capitalization
$36.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Elutia is a medical technology company focused on developing biologic products for use in surgery. Its portfolio includes envelopes designed to support cardiac implantable electronic devices, such as pacemakers and defibrillators.

The company’s products include CanGaroo, an extracellular-matrix envelope designed to help secure and support implanted devices, and EluPro, an antibiotic-eluting envelope intended to help reduce the risk of infection associated with these devices.

Elutia was formerly known as Aziyo Biologics and adopted its current name in 2023 as it focused its business on drug-eluting biologic technologies.

AI Generated. May Contain Errors.

Elutia Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
7th Percentile Overall Score

ELUT MarketRank™: 
0.35061176161 of 5 stars

Elutia scored higher than 7% of companies evaluated by MarketBeat, and ranked 822nd out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Elutia has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Elutia has only been the subject of 1 research reports in the past 90 days.

  • Read more about Elutia's stock forecast and price target.
  • Price to Book Value per Share Ratio

    Elutia has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.09% of the float of Elutia has been sold short.
  • Short Interest Ratio / Days to Cover

    Elutia has a short interest ratio ("days to cover") of 0.48, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elutia has recently increased by 119.63%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Elutia does not currently pay a dividend.

  • Dividend Growth

    Elutia does not have a long track record of dividend growth.

  • News Sentiment

    Elutia has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Elutia this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    2 people have added Elutia to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Elutia insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.80% of the stock of Elutia is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    74.03% of the stock of Elutia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Elutia's insider trading history.
Receive ELUT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elutia and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ELUT Stock News Headlines

A free stock pick, from me to you
Elon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.tc pixel
Elutia Q3 Earnings Call Highlights
Transcript : Elutia Inc., Q3 2026 Earnings Call, Nov 05, 2026
See More Headlines

ELUT Stock Analysis - Frequently Asked Questions

Elutia's stock was trading at $0.6927 at the start of the year. Since then, ELUT stock has increased by 18.4% and is now trading at $0.82.

Elutia Inc. (NASDAQ:ELUT) issued its earnings results on Thursday, November, 5th. The company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.11. The company had revenue of $1.14 million for the quarter, compared to the consensus estimate of $1 million. Elutia had a net margin of 546.70% and a negative trailing twelve-month return on equity of 140.53%.
Read the conference call transcript
.

Elutia (ELUT) raised $50 million in an IPO on Wednesday, October 7th 2020. The company issued 2,941,176 shares at a price of $16.00-$18.00 per share.

Elutia's top institutional investors include AIGH Capital Management LLC (5.72%). Insiders that own company stock include Highcape Capital, LP, Matthew Ferguson, C Randal Mills, Kevin Rakin, Guido J Neels, David Colpman and Brigid Makes.
View institutional ownership trends
.

Shares of ELUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/05/2026
Today
11/15/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:ELUT
CIK
1708527
Employees
26
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
$1.11
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$53.38 million
Net Margins
546.70%
Pretax Margin
-279.60%
Return on Equity
-140.53%
Return on Assets
-54.54%

Debt

Debt-to-Equity Ratio
0.53
Current Ratio
2.63
Quick Ratio
2.61

Sales & Book Value

Annual Sales
$12.29 million
Price / Sales
2.96
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.65 per share
Price / Book
1.26

Miscellaneous

Outstanding Shares
44,290,000
Free Float
36,406,000
Market Cap
$36.32 million
Optionable
Not Optionable
Beta
0.93
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:ELUT) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners